Carole Faig
Director/Board Member presso CUE HEALTH INC.
Patrimonio netto: 208 097 $ in data 31/03/2024
Profilo
Carole T.
Faig is an Independent Director at Henry Schein, Inc. and Cue Health, Inc. She is also a Director at QuVa Pharma, Inc. and an Independent Director at Affinia Therapeutics, Inc. Previously, she worked as a Partner at Ernst & Young LLP.
She received her undergraduate degree from Sam Houston State University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
HENRY SCHEIN, INC.
0.00% | 04/03/2024 | 2 604 ( 0.00% ) | 196 654 $ | 31/03/2024 |
CUE HEALTH INC.
0.04% | 31/03/2024 | 60 543 ( 0.04% ) | 11 443 $ | 31/03/2024 |
Posizioni attive di Carole Faig
Società | Posizione | Inizio |
---|---|---|
CUE HEALTH INC. | Director/Board Member | 01/01/2021 |
HENRY SCHEIN, INC. | Director/Board Member | 18/12/2023 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Director/Board Member | 01/09/2021 |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | Director/Board Member | - |
Precedenti posizioni note di Carole Faig
Società | Posizione | Fine |
---|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Formazione di Carole Faig
Sam Houston State University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
HENRY SCHEIN, INC. | Distribution Services |
CUE HEALTH INC. | Health Technology |
Aziende private | 3 |
---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | Health Technology |
- Borsa valori
- Insiders
- Carole Faig